Given the presumed proinflammatory nature, these cytokines are putative targets for preventing aneurysm progression.
A bdominal aortic aneurysm (AAA) is a common disease affecting 5% of males over the age of 65 and results in 15 000 deaths annually. 1 The disease is slowly progressive ultimately leading to rupture if not treated operatively. Most AAAs are asymptomatic until rupture, which leads to death in >65% of patients. 2 Although the initiating events are not well understood, it has been established that inflammation is a major contributing factor to aneurysm progression. 3 Patient studies and animal models have been used to better understand the role of inflammation in aneurysm development and progression. One widely used model is the calcium chloride model (CaCl 2 ), which recapitulates features of human AAA including inflammatory cell invasion, MMP (matrix metalloproteinase) upregulation, matrix degradation, and aneurysm formation. 4 Aneurysms induced by CaCl 2 are an accepted and reliable model for chemical induction of AAAs. [5] [6] [7] To understand how the inflammatory process can led to aneurysm formation, we assessed the differential cytokine production by inflammatory cells from patients with AAA and a matched atherosclerotic group with normal aortic diameter. IL (interleukin)-1β was one of the few cytokines differentially expressed. Both IL-1β and TNF-α (tumor necrosis factor-α) have been associated with the progressive inflammatory process that promotes aneurysm progression. 8, 9 The inflammasome NLRP3 (NLR family pyrin domain containing 3) has been implicated in AAA development after induction of angiotensin II and results in IL-1β release from macrophages. 10, 11 Interestingly, IL-1β blockade has been shown to have equivocal effects on atherosclerosis in a murine model. February 2018 in diseases such as rheumatoid arthritis, Crohn disease, and ulcerative colitis. [13] [14] [15] Pharmaceutical companies have devoted significant time and research into developing inhibitors of these and other inflammatory cytokines to help manage these diseases. However, relatively few studies directly compare their efficacies. 16 The use of IL-1β inhibitors in more common pathologies, such as rheumatoid arthritis, have not been as effective as anticipated (URL: http://www.clinicaltrials.gov. Unique identifier: NCT00424346). IL-1β inhibitors are effective in a small subset of specific diseases. 17, 18 TNF-α blockade has emerged as a more effective clinical tool. 19 The reason for these differences in clinical effectiveness of these 2 cytokine inhibitors is not well understood.
Johnston et al 8 has shown that genetic and pharmacological inhibition of IL-1β in the elastase infusion murine model protects against AAA development. This led to a recent clinical trial using an IL-1β antibody to inhibit the expansion of small AAA in humans (URL: http://www.clinicaltrials.gov. Unique identifier: NCT02007252). Based on the differential IL-1β expression, we further assessed circulating levels of IL-1β. These results led us to evaluate the role of IL-1β deletion in the CaCl 2 model of AAA. Unexpectedly, IL-1β deletion had a very distinct effect compared with TNF-α, another prototypical proinflammatory cytokine. We further investigated the mechanism of this differential effect by studying macrophages from IL-1β −/− and TNF-α −/− null mice.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

IL-1β Differentiated Between AAA and Controls
AAAs are inflammatory in nature with cytokines IL-1β and TNF-α thought to promote aneurysm progression (Table 1) . Evidence for the potential roles of IL-1β includes presence in aneurysm tissue and murine data suggesting that it promotes aneurysm development. Using high sensitivity ELISA, IL-1β was not detectable in the plasma of patients with AAA (n=9), but it was detectable in most samples (7/10) in the control group (n=10; Figure 1 ). Fisher exact test comparing the AAA versus control patients demonstrated a P value of 0.003 ( Table 2 ). Levels of IL-1β were low in control patients, but the difference remained statistically significant (t test, P=0.015). Although both atherosclerosis and abdominal aneurysms are associated with systemic inflammation, these data demonstrate IL-1β levels differentiate between patients with these 2 disease processes.
AAA Formation Was Enhanced by IL-1β Inhibition
We used both IL-1R −/− and IL-1β −/− mice to study the effects on aneurysm formation using a murine AAA model established in our laboratory. Neither the IL-1R −/− nor IL-1β
showed inhibition of aneurysm formation. The IL-1R −/− mice developed larger aneurysms compared with their wild-type (WT) controls (P<0.05; Figure 2 ). This was unexpected given previously published results in other murine AAA models. 8 Histological imaging also demonstrated similar levels of lamellar destruction in all CaCl 2 -treated mice ( Figure 3A ). Quantitative data ( Figure 3A ; bar graph) shows percentage of aortic lamellar degradation. IL-1R −/− had significantly higher levels of lamellar fragmentation compared with the WT. Zymography demonstrated similar levels of expression of both latent and active MMP-9 and MMP-2 ( Figure 3B ). The analysis included 5 to 10 samples in each group and a representative gel is illustrated. Aortic wall thickness was also assessed, but was not different among the CaCl 2 -treated mice. There was a significant difference in aortic wall thickness between the NaCl-and CaCl 2 -treated mice (P<0.05; Materials in the online-only Data Supplement).
IL-1β and TNF-α Exhibited Different Effects on Macrophage Activation
IL-1β and TNF-α have traditionally been considered among the most potent proinflammatory cytokines. Our previous work demonstrated that TNF-α inhibition prevents aneurysm formation, protects from matrix degradation, and blocks MMP expression partly by blocking macrophage activation. 9 We realized that we could use our aneurysm model to better understand the disparate effects of these 2 important cytokines. We investigated the effects of each on macrophage polarization. Bone marrowderived macrophages from IL-1β −/− and TNF-α −/− mice were treated with LPS (lipopolysaccharide) and IFN-γ (interferon-γ) to promote polarization to the M1 phenotype. Quantitative real time-polymerase chain reaction analysis of macrophage gene expression demonstrated elevated M2 marker expression (IL-10, cluster of differentiation [CD]206) in TNF-α −/− macrophages compared with WT macrophages ( Figure 4A ). IL-10 and CD206 were not increased in IL-1β −/− macrophages when exposed to LPS and IFN-γ. M1 markers were not different among the groups. These data demonstrated important differences in the macrophage response to IL-1β and TNF-α deletion. We have demonstrated previously the importance of M1 polarization to aneurysm formation in the CaCl 2 model. 20 Because of the unexpected results in the IL-1β −/− mice, we performed an ELISA assay of macrophages derived from each of the mouse strains used for this study. IL-1β was not detectable in the cell culture media from any of the mice. Macrophage cell lysates from the IL-1β −/− mouse confirmed lack of IL-1β expression. However, there was a compensatory increase in IL-1β levels in the IL-1R −/− mice compared with the expression in the WT mice. There was no increase in IL-1β in the TNF-α −/− mice ( Figure 4B ). The levels found in the cell lysate would reflect total, rather than secreted, IL-1β. Given effects observed on ex vivo experiment described above, we next studied the effects of infusing activated macrophages into WT mice. We assessed the effects at the 3-day and 6-week time point. The 3-day time point was chosen based on previous observations demonstrating high levels of M1 marker expression in the aorta at that time point, whereas the 6-week time point was chosen to monitor long-term effect on aortic expansion. Bone marrow-derived macrophages from IL-1β −/− and TNF-α −/− mice were polarized to an M1 phenotype with LPS and INF-γ. Cells were given intravenously via tail vein injection before aneurysm induction. To determine if the infused macrophages reached the aortic tissue, cells were fluorescently labeled and aortic tissue homogenates were assessed on day 3 by flow cytometry. We found that 0.05% of all aortic cells were CFSE (carboxyfluorescein succinimidyl ester) positive demonstrating aortic infiltration by infused macrophages. Infusion of activated macrophages from IL-1β −/− mice resulted in aortic dilation similar to mice infused with M1-activated macrophages from WT mice ( Figure 5A ). In contrast, mice infused with activated macrophages from TNF-α −/− mice developed smaller aneurysms at 3 days and 6 weeks (P<0.05; Materials in the online-only Data Supplement; Figure 5 ). This partial inhibition is consistent with our observations of increased M2 marker expression by activated macrophages from TNF-α −/− mice ( Figure 4A ).
Discussion
Inflammation is the hallmark of aneurysm tissue with T-cells and macrophages being predominant. Macrophages exist in either a proinflammatory (M1) or anti-inflammatory (M2) state. We have shown previously that M1 macrophage polarization is critical to aneurysm formation in the CaCl 2 model. IL-1β (interleukin-1β) levels in the plasma of control and patients with abdominal aortic aneurysm (AAA). Blood samples were collected and compared from controls (n=10) with normal aortic diameter to patients with AAA (n=9). The concentration of IL-1β in the plasma of control and patients with AAA were determined using an ELISA assay as shown in the bar graph. IL-1β was undetectable in the plasma of patients with AAA. Fisher exact test was conducted (P=0.003). Levels of IL-1β were low in patients with control but the difference remained statistically significant (t test; P=0.015). ND indicates not detectable. Blood samples were collected and compared from controls (n=10) with normal aortic diameter to patients with AAA (n=9). The concentration of IL-1β in the plasma of control and patients with AAA were determined using an ELISA assay as shown in the bar graph. IL-1β was undetectable in the plasma of patients with AAA. Fisher exact test was used. AAA indicates abdominal aortic aneurysm; IL, interleukin.
Figure 2. The effects of IL (interleukin)-1R
−/− and IL-1β −/− on aortic diameter. Relative changes of aortic diameter were compared among wild-type (WT) mice (NaCl, n=7; CaCl 2 , n=15), IL-1R −/− mice (NaCl, n=9; CaCl 2 , n=11), and IL-1β −/− mice (NaCl, n=17; CaCl 2 , n=15). Aneurysm induction was performed using the described protocol with CaCl 2 and NaCl. Student t test was used for analysis. *P<0.05 compared with NaCl-treated controls; #P<0.05 compared with CaCl 2 -treated WT. February 2018 Usui et al 11 demonstrated that angiotensin II infusion stimulated the inflammasome NLRP3 and subsequently led to the release of IL-1β, IL-6, and CCL2 (C-C motif chemokine ligand 2) from macrophages. This was mediated through mitochondria-derived reactive oxygen species resulting in AAA development. 10 The authors suggest that blocking NLRP3 inflammasome could be a useful strategy because it downregulates a host of inflammatory mediators. Our data suggests this effect is mediated through cytokines other than IL-1β. The differential expression we observed in cytokine expression between AAA and control patients prompted us to further investigate the role of IL-1β in the CaCl 2 murine model of AAA. Unexpectedly, we found that targeted deletion of IL-1β or its receptor, did not block aneurysm formation. Given the potential role that IL-1β can play in macrophage activation, we investigated the effects of its deletion on macrophage polarization in comparison to another proinflammatory cytokine, TNF-α. When macrophages were polarized to an M1 phenotype, TNF-α −/− macrophages expressed higher levels of M2 cytokines in contrast to IL-1β −/− macrophages. Consistent with these results, infusion of M1 polarized TNF-α −/− macrophages inhibited aneurysm formation; M1 polarized IL-1β −/− macrophages exhibited similar effects to M1 polarized WT macrophages showing no inhibition in AAA progression. Taken together, these data demonstrate that IL-1β deletion does not block M1 macrophage polarization. This may explain why IL-1β inhibition has been less efficacious compared with TNF-α inhibition in many inflammatory conditions. [16] [17] [18] [19] Preliminary studies with inflammatory cells isolated from AAA and control patients suggested differential expression of IL-1β. We analyzed plasma IL-1β levels in these 2 groups using high sensitivity ELISA. We found small, but significant differences in IL-1β expression. IL-1β was not detectable in any patients with AAA, whereas low levels of expression were detected in most control patients. Finding that IL-1β was expressed in controls and not patients with AAA was unexpected. We attempted to cross-validate these findings in our mouse model. Choosing control patients for studying AAA is challenging. We selected age-matched patients with peripheral or cerebrovascular disease, but with normal diameter aortas. One limitation of our study is that we did not have access to all patient medication records. Most likely, both groups of patients were on aspirin and statins, which could indirectly affect the level of inflammatory cytokines. Ideally, we would have , and IL-1β −/− mice. MMP-2 and MMP-9 expression were quantified (right, bar graph) using ImageJ software. ANOVA was used for the analysis. There was no significant difference in MMP-2 and MMP-9 expression among the 3 CaCl 2 -treated groups. *P<0.05 compared with NaCl-treated WT mice.
assessed cytokine levels in aortic tissue from these patients; however, endovascular therapies have greatly reduced access to these tissues. Identifying circulating biomarkers that reflect aneurysm biology will be valuable to AAA research.
Animal models are most useful for understanding disease pathogenesis. We investigated the mechanisms of IL-1β inhibition in the CaCl 2 model of AAA. In the elastase infusion model, Johnston et al 8, 21 found that aneurysm formation was attenuated by IL-1β deletion or antagonism. We have shown previously that TNF-α inhibition or deletion prevented aneurysm formation. 9 Given the known similarities between actions of IL-1β and TNF-α, we were surprised to find that deletion of IL-1β or its receptor did not prevent aneurysm formation. Furthermore, its deletion did not reduce MMP-9 or MMP-2 levels, which are known to correlate with AAA. In fact, we observed a trend toward increased diameter in IL-1β −/− mice, whereas the IL-1R −/− mice actually showed a significant increase in aortic diameter compared with WT. These discrepancies between our observations and those of Johnston et al 8, 21 can only be attributed to differences between the 2 models because the same mice were used in both studies. The elastase infusion model combines significant mechanical dilation with subsequent inflammation producing aneurysms within 2 weeks. 8 The CaCl 2 model relies entirely on a local inflammatory response and polarization of invading macrophages to an M1 phenotype. In normal wound healing, the M2 macrophages reduce inflammation and promote fibrosis after several weeks. 22, 23 Although the precise role of macrophage polarization in elastase infusion model is not known, the discrepant observations related to IL-1β inhibition are likely the results of difference in the macrophage phenotype. The effects of IL-1β manipulation on M2 polarization may not manifest in this more acute model. 24 Although none of the animal models can accurately reproduce all of the features of human AAA, the results obtained in CaCl 2 model accurately reflected the lack of clinical efficacy of IL-1β inhibition observed in patients with AAA. The clinical trial using an IL-1β antibody was terminated early because of lack of efficacy and futility (URL: http:// www.clinicaltrials.gov. Unique identifier: NCT02007252). In contrast, the CANTOS trial (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) recently demonstrated efficacy of IL-1β antibodies in reducing adverse cardiac-related events in patients with atherosclerotic coronary artery disease. 25 However, this small benefit was offset by an increased risk of fatal infection and no observed effect on cardiovascular mortality. 26 IL-1β and TNF-α have long been considered prototypical inflammatory cytokines. As such, they have been targeted as possible treatments for several immune mediated diseases. [13] [14] [15] Previous studies have shown profound inhibition of aneurysm formation with antagonism of TNF-α in murine models of AAA. 9 Therefore, we expected similar results from IL-1β inhibition. Considering the inflammatory nature of both IL-1β and TNF-α, we were surprised to find decreased levels of IL-1β in patients with AAA and no inhibition of aneurysm formation with IL-1β deletion in the murine AAA model. Clinical studies using TNF-α antibodies have identified anti-inflammatory effects among different white blood cell populations including macrophages. 27 We have recently demonstrated the critical role of macrophage polarization toward the M1 phenotype in aneurysm formation. 20 In this study, we confirmed the presence of infused macrophages in the aortic tissue. This demonstrates local activity by infused macrophages; however, the relatively low proportion does not exclude systemic immune modulation. Using IL-1β −/− or TNF-α −/− macrophages, we identified different effects after promoting the M1 phenotype by exposure to LPS and IFN-γ. Cells lacking the expression of TNF-α in this study, expressed higher levels of M2 cytokines suggesting that TNF-α antagonism attenuates the destructive effects of M1 macrophages. Evidence of the protective effects of TNF-α antagonism were shown by the reduction in aneurysm size in the mice infused with activated macrophages from TNF-α −/− mice. Taken together, we demonstrated that deletion of IL-1β and TNF-α had very different effects on macrophage polarization. Human aneurysm tissue displays an abundance of infiltrating macrophages. Considering that macrophages may have significant anti-inflammatory effects, regulating the macrophage phenotype could alter the course of aneurysm disease. Using the CaCl 2 aneurysm model, we have identified a mechanism that may explain the difference in clinical efficacy of IL-1β versus TNF-α antagonism. Our studies suggest that TNF-α, rather than IL-1β, blockade would be more effective in diseases associated with M1 macrophage polarization including AAA. 
